Efatutazone clinical trials
Also written CS-7017.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses efatutazone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 3
Daiichi Sankyo (7) · Alliance for Clinical Trials in Oncology (2) · Daiichi Sankyo Co., Ltd. (2) · Georgetown University (1)
Studies
Open first, then newest update. How each study uses efatutazone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by SurgeryCompletedPhase 2Alliance for Clinical Trials in OncologyNCT02249949Written as efatutazone
- Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid CancerCompletedPhase 2Alliance for Clinical Trials in OncologyNCT02152137Written as efatutazone
- CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1Daiichi Sankyo Co., Ltd.NCT01199068Written as CS-7017
- Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line ChemotherapyTerminatedPhase 2Daiichi SankyoNCT00986440Written as CS-7017
- Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic CancerCompletedPhase 1Daiichi SankyoNCT00408434Written as CS-7017
- Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017CompletedPhase 1Daiichi SankyoNCT00881569Written as CS-7017
- A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With PaclitaxelTerminatedPhase 1/2Daiichi SankyoNCT00603941Written as CS-7017
- CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1Daiichi Sankyo Co., Ltd.NCT01199055Written as CS-7017
- Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung CancerCompletedPhase 2Daiichi SankyoNCT01101334Written as CS-7017
- Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung CancerCompletedPhase 2Daiichi SankyoNCT00806286Written as CS7017 tablets
- Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line TherapyCompletedPhase 2Daiichi SankyoNCT00967616Written as CS7017
- Phase I Study of CS-7017 and BexaroteneTerminatedPhase 1Georgetown UniversityNCT01504490Written as CS-7017 and Bexarotene
Codes
What other systems call efatutazone · ClinicalTrials.gg INT004912
- MeSH (NLM) C510342efatutazoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M17ILL71MCEFATUTAZONEConfirmed FDA, NLM, Wikidata
- Wikidata Q21083321efatutazoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83819EfatutazoneOne source FDA
- DrugBank DB11894One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C510342 | efatutazone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M17ILL71MC | EFATUTAZONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21083321 | efatutazone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83819 | Efatutazone | One source FDA |
| DrugBank | DB11894 | — | One source Wikidata |
Also registered as efatutazone dihydrochloride (UNII 76B44WEA8O).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.